Walgreens Clears Key FDA Hurdle as Sycamore Advances Asset Sale

The U.S. Food and Drug Administration (FDA) issued a formal close-out letter today at 15:49 GMT, resolving a significant regulatory issue for Walgreens. This development coincides with reports that Sycamore Partners is accelerating the full sale process for VillageMD. For former shareholders holding contingent value rights (CVRs), these events are critical to determining the final payout, which could reach up to USD 3.00 per share.

Today’s action by the FDA closes Warning Letter #2512, confirming that Walgreens has satisfactorily addressed all required corrective measures. The compliance issues pertained to product listing and labeling for the company’s "Sensitive Extra Whitening" product line, identified under NDC 0363-1588.

Since Sycamore Partners acquired Walgreens in August 2025, management has pursued an aggressive store optimization strategy. This included the closure of approximately 500 underperforming locations by the end of 2025, with a long-term plan to shutter 1,200 stores. The resolution of this FDA warning suggests the company’s broader restructuring may also be mitigating legal and supervisory risks.

Should investors sell immediately? Or is it worth buying Walgreens?

Implications of the VillageMD Divestiture

Internal sources indicate Sycamore is now moving more swiftly to complete the sale of VillageMD. The transaction’s outcome is directly tied to the contingent value rights retained by former Walgreens shareholders. These CVRs entitle holders to a tiered payout, with a maximum potential of USD 3.00 per share, contingent on the ultimate sale value achieved for the Village Medical, Summit Health, and CityMD business units.

Recent interest from strategic buyers has improved prospects for a higher valuation. However, the definitive CVR payout amount remains uncertain until the final transaction price and terms are settled.

Looking Ahead to 2026

The first half of 2026 is expected to be dominated by finalizing the VillageMD sale. Once forbearance agreements and strategic valuations are complete, former shareholders will receive clarity on the CVR valuation. It is important to note that the previous stock ticker is no longer active; the value of the non-transferable CVRs is solely dependent on the success of these divestitures. For Walgreens under Sycamore’s ownership, maintaining regulatory compliance and executing its store network optimization will remain central to ongoing stabilization efforts.